Related Experiment Videos
Percutaneous coronary intervention versus medical therapy for coronary heart disease
1Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, 315 MRB II, Nashville, TN 37232-6300, USA. david.maron@mcmail.vanderbilt.edu
Insights
Percutaneous coronary intervention (PCI) offers angina relief for stable coronary heart disease (CHD) patients but may increase cardiac event risk compared to medical therapy. Further research is needed to define PCI's role in CHD treatment.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Trials
Background:
- Medical therapy effectively reduces myocardial infarction and death in stable coronary heart disease (CHD).
- Limited evidence exists on the impact of percutaneous coronary intervention (PCI) on hard endpoints in stable CHD patients.
Purpose of the Study:
- To evaluate the effectiveness of PCI compared to medical therapy in patients with stable or recently stabilized CHD.
- To address limitations of previous trials, including small sample sizes and exclusion of high-risk subjects.
Main Methods:
- Comparison of PCI versus medical therapy in four randomized controlled trials.
- Analysis of outcomes including angina, exercise tolerance, and cardiac events.
- Consideration of factors like stent use, cost-effectiveness, and risk factor intervention.
Main Results:
- PCI improved angina and exercise tolerance compared to medical therapy.
- Medical therapy may be preferable regarding the risk of cardiac events.
- Previous studies were limited by small sample sizes and patient selection.
Conclusions:
- The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial aims to clarify PCI's role in stable CHD.
- Further investigation is required to optimize treatment strategies for stable CHD patients.
Abstract:
Medical therapy reduces myocardial infarction and death in patients with stable coronary heart disease (CHD). In contrast, there is little evidence available to evaluate the impact of percutaneous coronary intervention (PCI) on hard endpoints in such patients. Four randomized, controlled trials have compared PCI with medical therapy. These studies have demonstrated that PCI results in an improvement in angina and exercise tolerance compared with medical therapy, but they also suggest that medical therapy may be preferable to PCI with respect to the risk of cardiac events. Interpretation of these studies has been limited by small sample size, exclusion of high-risk subjects, no or reduced use of stents, lack of a cost- effectiveness evaluation, and absence of risk factor intervention (except for Atorvastatin versus Revascularization Treatment, which used aggressive low-density lipoprotein lowering with atorvastatin in the medical group only). The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial will permit better definition of the role of PCI in the treatment of stable or recently stabilized patients with CHD.